An understanding of the complex pathologies involved in patients with neurodegenerative diseases is integral to the identification of biomarkers and potential treatment methods for individuals who suffer from Alzheimer’s, Parkinson’s, and ALS. Here, we look at the development of dedicated biomarker strategies for helping to combat neurodegeneration.

Simon Gao of Genentech discusses his background in clinical imaging and the impact that AI-based approaches may have on biomarker discovery.

A key utility of untargeted metabolomics is for detecting key metabolites as indicators of human health and disease status. AI/ML approaches can help to accelerate the verification and validation of metabolomics data.

In Conversation With Michael Schnall-Levin, Chief Technology Officer & Founding Scientist, 10x Genomics